Filed in Last 1 weekBrowse disclosures by filing date
Reported role All roles
Filed Nov 1, 2026 – Nov 7, 2026
Newest disclosures first · Trade dates may be earlier
Loading insider disclosures…
Sources & coverage
These are available SEC Form 4 purchase and sale records. The view excludes awards, gifts, option exercises and other transaction types. Large shareholders can include investment firms as well as individuals.
The period follows filing dates. Each row also shows when the transaction occurred. Reported value is shares multiplied by the reported price; a missing or zero imported price is shown as unavailable.
Weekly highlights cover the last seven filing dates and count distinct reporting-owner names. They feature the largest purchase and sale totals among companies with complete amounts in the available records, independently of the filters below.
Coverage is partial. Expand a transaction for the reporting owners, ownership, trading-plan disclosure and footnotes available in that record. Older records may only identify the first reporting owner. Missing context is shown as unavailable; the original filing remains the source.
Role filters use reported officer titles and ownership relationships, so one filing can match more than one role. A purchase transaction code does not establish that a trade took place on the open market.
Position & filing details for Kelley Shannon T, MDGL, filed Nov 6, 2026
Sold 9.4% of reported shares11,474 before → 10,397 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kelley Shannon T · General Counsel
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2026.
Position & filing details for Hoffman Michael B, ANVS, filed Nov 6, 2026
Added 148.6% to reported shares3,364,883 before → 8,364,883 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Hoffman Michael B · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The 5,000,000 shares of Common Stock and 5,000,000 warrants described in Table I and Table II, respectively, were acquired for a combined price of $1.00 per share.
F2 The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for Hug Joshua, RELY, filed Nov 6, 2026
Sold 0.21% of reported shares2,642,389 before → 2,636,889 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Hug Joshua · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This transaction was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025.
F2 Weighted average price. These shares were sold in multiple transactions at prices ranging from $20.74 to $23.00 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 1.4% of reported shares1,678,609 before → 1,654,713 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for RUBINSTEIN JULIE, ADPT, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
RUBINSTEIN JULIE · President and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for An Jing, LKNCY, filed Nov 6, 2026
Sold 6.9% of reported shares245,784 before → 228,784 after
Change in this reported direct American Depositary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
An Jing · Chief Financial Officer
Filing facts
Security
American Depositary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Each American Depositary Share ("ADS") represents eight Class A Ordinary Shares.
Position & filing details for Skelly Noreen E, ROAD, filed Nov 6, 2026
Added 2.9% to reported shares3,434 before → 3,534 after
Change in this reported indirect Class A Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Skelly Noreen E · Director
Filing facts
Security
Class A Common Stock
Ownership
Indirect · By Skelly Revocable Trust
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The reported shares are held by a trust for which the reporting person serves as co-trustee, and in such capacity shares the power to vote and direct the disposition of such shares.
F2 Includes 8,000 restricted shares of Class A common stock, $0.001 par value, of Construction Partners, Inc. with time-based vesting criteria previously granted to the reporting person under the Construction Partners, Inc. 2018 Equity Incentive Plan that vest as follows: (i) 5,333 shares on January 1, 2027 and (ii) 2,667 shares on January 1, 2028. Under the terms of the award agreement, the reporting person has sole voting power with respect to the shares.
Position & filing details for BAKER BROS. ADVISORS LP, MDGL, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
BAKER BROS. ADVISORS LP · Director
Baker Bros. Advisors (GP) LLC · Director
BAKER FELIX · Director
BAKER JULIAN · Director
667, L.P. · Director
Baker Brothers Life Sciences LP · Director
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See Footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 0.80% of reported shares1,603,798 before → 1,591,006 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 0.74% of reported shares1,591,006 before → 1,579,292 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 0.88% of reported shares1,579,292 before → 1,565,453 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for BAKER BROS. ADVISORS LP, MDGL, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
BAKER BROS. ADVISORS LP · Director
Baker Bros. Advisors (GP) LLC · Director
BAKER FELIX · Director
BAKER JULIAN · Director
667, L.P. · Director
Baker Brothers Life Sciences LP · Director
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See Footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Position & filing details for RUBINSTEIN JULIE, ADPT, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
RUBINSTEIN JULIE · President and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Position & filing details for ACEVEDO SYLVIA, QCOM, filed Nov 6, 2026
Sold 0.67% of reported shares9,068.4237 before → 9,007.7546 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 0.88% of reported shares1,654,713 before → 1,640,200 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Sharma Pooja, PRCT, filed Nov 6, 2026
Sold 4.2% of reported shares111,181 before → 106,471 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Sharma Pooja · Chief Strat/Marketing Officer
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 These shares were sold by the reporting person pursuant to the Issuer's sell-to-cover process for tax withholding obligations in connection with the vesting of the Restricted Stock Units on November 5, 2026.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 1.2% of reported shares1,640,200 before → 1,620,199 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 1% of reported shares1,620,199 before → 1,603,798 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Pollard Charles W., ALGT, filed Nov 6, 2026
Sold 38.5% of reported shares26,000 before → 16,000 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Pollard Charles W. · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Price reported is average price per share. Shares were sold at prices per share ranging from $93.00 to $93.09.
Position & filing details for BAKER BROS. ADVISORS LP, MDGL, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
BAKER BROS. ADVISORS LP · Director
Baker Bros. Advisors (GP) LLC · Director
BAKER FELIX · Director
BAKER JULIAN · Director
667, L.P. · Director
Baker Brothers Life Sciences LP · Director
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See Footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Position & filing details for Ehrlichman Matt, PRCH, filed Nov 6, 2026
Sold 0.13% of reported shares15,445,242 before → 15,425,790 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Ehrlichman Matt · CEO, CHAIRMAN AND FOUNDER · Director · 10% owner
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The sales represented on this Form 4 were effected pursuant to a previously disclosed Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025 (the "Trading Plan") for personal tax planning purposes and to satisfy tax obligations. The Trading Plan covers the sale of up to an aggregate of 584,998 shares of the Issuer's common stock. All terms of the Trading Plan, including the number of shares to be sold and the minimum sale prices, were fixed at adoption. As of the date of this filing, the Reporting Person has no other Rule 10b5-1 trading plan in effect.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for KINDER RICHARD D, KMI, filed Nov 6, 2026
Added 0.20% to reported shares246,212,353 before → 246,712,353 after
Change in this reported direct Class P Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
KINDER RICHARD D · Executive Chairman · Director · 10% owner
Filing facts
Security
Class P Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.92 to $29.99 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for Equels Thomas K, AIM, filed Nov 6, 2026
Added 10.7% to reported shares189,747 before → 210,046 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for CHAPLIN ANN C, QCOM, filed Nov 6, 2026
Sold 5.2% of reported shares28,772 before → 27,271 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
CHAPLIN ANN C · EVP, GenCounsel&CorpSecretary
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.
Position & filing details for Shah Prem S, CVS, filed Nov 6, 2026
Added 36.9% to reported shares64,661.1575 before → 88,516.1575 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for O'Day Daniel Patrick, GILD, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
O'Day Daniel Patrick · Chairman & CEO · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
F2 Sale prices for the transactions reported range from $175.05 to $175.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3 The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Position & filing details for Orn Jonsson Sigurgeir, BETR, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Orn Jonsson Sigurgeir · Chief Technology Officer
Filing facts
Security
Class A Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.80 to $19.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A common stock.
F3 The RSUs were granted on February 11, 2026 and vest quarterly over four years in 16 nearly equal installments, subject to the Reporting Person's continued service with the Issuer.
Position & filing details for Kurtz George, CRWD, filed Nov 6, 2026
Sold 0.03% of reported shares7,279,987 before → 7,277,709 after
Change in this reported direct Class A common stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kurtz George · PRESIDENT AND CEO · Director
Filing facts
Security
Class A common stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Includes shares sold pursuant to a 10b5-1 plan adopted on January 16, 2026.
F2 This transaction was executed in multiple trades at prices ranging from $237.82 to $238.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Position & filing details for O'Hara Kevin P, HSTM, filed Nov 6, 2026
Sold 17.5% of reported shares22,901 before → 18,901 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
O'Hara Kevin P · Executive Vice President
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 This transaction was executed in multiple trades at prices ranging from $30.00 to $32.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Position & filing details for Collier Michael Manning, HSTM, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Collier Michael Manning · Executive Vice President
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 This transaction was executed in multiple trades at prices ranging from $30.23 to $31.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F2 The exercise and sale were effected through a broker-assisted cashless exercise.
F3 This transaction was executed in multiple trades at prices ranging from $29.41 to $30.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Position & filing details for Altschuler Randolph, XMTR, filed Nov 6, 2026
Sold 0.44% of reported shares536,366 before → 534,008 after
Change in this reported indirect Class A Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Altschuler Randolph · Director
Filing facts
Security
Class A Common Stock
Ownership
Indirect · Held by spouse
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Represents shares sold in a transaction that was effected automatically pursuant to a Rule 10b-5 trading plan adopted by the reporting person's spouse at least 90 days prior to the trading date.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.49 to $105.36, inclusive. The reporting person undertakes to provide to Xometry, Inc., any security holder of Xometry, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price in the ranges set forth in footnotes (2) through (8) to this Form 4.
Position & filing details for ROTHBLATT MARTINE A, UTHR, filed Nov 6, 2026
Sold 0.04% of reported shares325,923 before → 325,803 after
Change in this reported indirect Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
ROTHBLATT MARTINE A · Chairperson & CEO · Director
Filing facts
Security
Common Stock
Ownership
Indirect · by Trust
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
Position & filing details for Mansueto Joseph D, MORN, filed Nov 6, 2026
Sold 0.03% of reported shares8,592,455 before → 8,589,523 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Mansueto Joseph D · Executive Chairman · Director · 10% owner
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.
F2 The transaction was executed in multiple trades at prices ranging from $244.4100 to $245.3400. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
Position & filing details for Reske James R, FCF, filed Nov 6, 2026
Sold 0.14% of reported shares69,238 before → 69,138 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Reske James R · EVP/Chief Financial Officer
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Award in 2024 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
F2 Award in 2025 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Award in 2026 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Position & filing details for RUBINSTEIN JULIE, ADPT, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
RUBINSTEIN JULIE · President and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Position & filing details for Kurtz George, CRWD, filed Nov 6, 2026
Sold 0.001% of reported shares7,283,109 before → 7,283,009 after
Change in this reported direct Class A common stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kurtz George · PRESIDENT AND CEO · Director
Filing facts
Security
Class A common stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Includes shares sold pursuant to a 10b5-1 plan adopted on January 16, 2026.
F2 This transaction was executed in multiple trades at prices ranging from $237.82 to $238.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Position & filing details for Reske James R, FCF, filed Nov 6, 2026
Sold 0.09% of reported shares70,098 before → 70,038 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Reske James R · EVP/Chief Financial Officer
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Award in 2024 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
F2 Award in 2025 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Award in 2026 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Position & filing details for Elsener William Thomas, MTDR, filed Nov 6, 2026
Added 0.78% to reported shares114,879 before → 115,779 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Elsener William Thomas · EVP, Reservoir Engineering
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Includes shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. Such acquisitions are exempt under Rule 16b-3
Position & filing details for King Ryan A, CHYM, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
King Ryan A · Co-Founder · Director
Filing facts
Security
Class A Common Stock
Ownership
Indirect · See footnote
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The shares are held by the King Family Trust, for which the Reporting Person serves as trustee.
F2 These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2025.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separated price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separated price within the range set forth in this footnote.
KY
KYNKayne Anderson Energy Infrastructure Fund, Inc.
Little Harrison JamesExecutive Vice President
Purchase$51,539Added 18.1% to reported shares3,900 shares · $13.22 / share
Position & filing details for Little Harrison James, KYN, filed Nov 6, 2026
Added 18.1% to reported shares21,552.502 before → 25,452.502 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F3 Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.63 to $22.60 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The securities are held by a family trust, of which the reporting person's spouse is the trustee.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F8 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") and 454 shares of Common Stock underlying unvested RSUs previously granted to each of Julian C. Baker, a managing member of the Adviser GP, and Dr. Raymond Cheong, a full-time employee of the Adviser, in their capacity as directors of the Issuer.
F5 The price reported in Column 4 is a weighted average price. These shares of Common Stock were traded by Life Sciences in multiple transactions at prices ranging from $366.77 to $367.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
F7 Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the board of directors of the Issuer and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
F8 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F9 The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $367.41 to $368.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") and 454 shares of Common Stock underlying unvested RSUs previously granted to each of Julian C. Baker, a managing member of the Adviser GP, and Dr. Raymond Cheong, a full-time employee of the Adviser, in their capacity as directors of the Issuer.
F5 The price reported in Column 4 is a weighted average price. These shares of Common Stock were traded by Life Sciences in multiple transactions at prices ranging from $366.77 to $367.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
F7 Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the board of directors of the Issuer and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
F8 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F9 The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $367.41 to $368.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F8 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") and 454 shares of Common Stock underlying unvested RSUs previously granted to each of Julian C. Baker, a managing member of the Adviser GP, and Dr. Raymond Cheong, a full-time employee of the Adviser, in their capacity as directors of the Issuer.
F5 The price reported in Column 4 is a weighted average price. These shares of Common Stock were traded by Life Sciences in multiple transactions at prices ranging from $366.77 to $367.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
F7 Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the board of directors of the Issuer and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
F8 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F9 The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $367.41 to $368.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 to $21.93 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.26 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.98 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.43 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Following the reported transactions, the Reporting Person beneficially owns 21,166,096 shares of the Issuer's common stock, including 6,416,712 shares held by West Equities, LLC, representing approximately 18.5% of the Issuer's outstanding common stock. This amount excludes 676,406 restricted stock units that are scheduled to vest more than 60 days following the date of this Form 4 and therefore are not included in the Reporting Person's beneficial ownership.
F7 Issuer common stock held by West Equities, LLC over which Reporting Person has sole voting and dispositive power.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F3 Includes shares to be issued in connection with the vesting of one or more restricted stock units (RSUs).
F4 This transaction was executed in multiple trades at prices ranging from $239.64 to $240.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $240.64 to $241.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $241.71 to $242.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $242.77 to $243.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $243.77 to $244.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $245.05 to $245.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10 This transaction was executed in multiple trades at prices ranging from $246.44 to $247.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $247.45 to $248.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12 This transaction was executed in multiple trades at prices ranging from $248.61 to $249.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13 This transaction was executed in multiple trades at prices ranging from $250.45 to $250.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F14 This transaction was executed in multiple trades at prices ranging from $251.73 to $252.40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F15 This transaction was executed in multiple trades at prices ranging from $214.06 to $214.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F16 This transaction was executed in multiple trades at prices ranging from $215.70 to $215.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F17 This transaction was executed in multiple trades at prices ranging from $216.48 to $217.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F18 This transaction was executed in multiple trades at prices ranging from $217.56 to $218.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F19 This transaction was executed in multiple trades at prices ranging from $218.57 to $219.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F20 This transaction was executed in multiple trades at prices ranging from $219.62 to $220.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F21 This transaction was executed in multiple trades at prices ranging from $220.76 to $221.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F22 This transaction was executed in multiple trades at prices ranging from $222.23 to $222.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F23 The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F4 The options vested according to the following schedule: 15% vested on December 9, 2021, 20% vested on December 9, 2022, 30% vested on December 9, 2023, and the remaining 35% vested on December 9, 2024.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.67 to $106.41, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.11 to $108.105, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.115 to $108.975, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.14 to $110.13, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.145 to $110.98, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.61 to $112.385, inclusive.
F10 This transaction was executed in multiple trades at prices ranging from $602.02 to $602.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F12 Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F13 Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F2 This transaction was executed in multiple trades at prices ranging from $592.58 to $593.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F4 This transaction was executed in multiple trades at prices ranging from $594.00 to $594.875. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $595.23 to $595.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $596.44 to $597.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $597.46 to $598.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $598.53 to $599.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $600.93 to $601.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The transaction was executed in multiple trades at prices ranging from $245.4900 to $246.4800. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
F4 The transaction was executed in multiple trades at prices ranging from $246.4900 to $247.4500. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
F5 The transaction was executed in multiple trades at prices ranging from $247.4950 to $248.4400. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
F6 The shares are held in grantor retained annuity trusts for the benefit of the reporting person and his children. The reporting person serves as trustee of the grantor retained annuity trusts.
F7 The shares are held in trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts.
F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F8 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 Includes shares to be issued in connection with the vesting of one or more restricted stock units (RSUs).
F4 This transaction was executed in multiple trades at prices ranging from $239.64 to $240.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $240.64 to $241.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $241.71 to $242.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $242.77 to $243.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $243.77 to $244.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $245.05 to $245.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10 This transaction was executed in multiple trades at prices ranging from $246.44 to $247.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $247.45 to $248.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12 This transaction was executed in multiple trades at prices ranging from $248.61 to $249.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13 This transaction was executed in multiple trades at prices ranging from $250.45 to $250.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F14 This transaction was executed in multiple trades at prices ranging from $251.73 to $252.40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F15 This transaction was executed in multiple trades at prices ranging from $214.06 to $214.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F16 This transaction was executed in multiple trades at prices ranging from $215.70 to $215.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F17 This transaction was executed in multiple trades at prices ranging from $216.48 to $217.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F18 This transaction was executed in multiple trades at prices ranging from $217.56 to $218.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F19 This transaction was executed in multiple trades at prices ranging from $218.57 to $219.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F20 This transaction was executed in multiple trades at prices ranging from $219.62 to $220.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F21 This transaction was executed in multiple trades at prices ranging from $220.76 to $221.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F22 This transaction was executed in multiple trades at prices ranging from $222.23 to $222.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F23 The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F1 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F5 Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F6 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F7 The shares are held by King Irrevocable Trust A, for which the Reporting Person serves as attorney-in-fact.
F8 The shares are held by King Irrevocable Trust M, for which the Reporting Person serves as attorney-in-fact.
F9 The shares are held by King Grantor Trust MV, for which the Reporting Person serves as attorney-in-fact.
F10 The shares are held by King Gift Trust AK, for which the Reporting Person serves as attorney-in-fact.
F11 The shares are held by King Gift Trust AV, for which the Reporting Person serves as attorney-in-fact.
F12 The shares are held by King Gift Trust CV, for which the Reporting Person serves as attorney-in-fact.
F13 The shares are held by King Gift Trust MK, for which the Reporting Person serves as attorney-in-fact.
F14 The shares are held by King Gift Trust NV, for which the Reporting Person serves as attorney-in-fact.
F15 The shares are held by Maureen Vergara, a member of the Reporting Person's family.
